insights_auto
Why is BVNKF up 7,13%?
Dive Deeperchevron_right
BVNKF:OTCMKTS
Bavarian Nordic A/S
USD 36,06
arrow_upward
+7,13%(+2,40) 1D
8 Okt., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BVNKF...
Open
USD 33,99
High
USD 36,06
Low
USD 33,99
Mkt. cap
2,76 mjd
Avg. vol.
7,00
Volume
208,00
52-wk high
USD 37,22
52-wk low
USD 27,69
Beta
1,46
Shares outstanding
79,26 m
No. of employees
2 k
Open
USD 33,99
High
USD 36,06
Low
USD 33,99
Mkt. cap
2,76 mjd
Avg. vol.
7,00
Volume
208,00
52-wk high
USD 37,22
52-wk low
USD 27,69
Beta
1,46
Shares outstanding
79,26 m
No. of employees
2 k
News stories
From web sources and news partners
The Copenhagen Post
·
2 uur gelede
Bavarian Nordic raises 2026 revenue forecast on stronger travel vaccine sales
Yahoo Finance
·
23 uur gelede
Bavarian Nordic lifts revenue, margin outlook on U.S. rabies vaccine demand
TradingView
·
1 dag gelede
Bavarian Nordic Raises Revenue, EBITDA Margin Forecasts
GlobeNewswire
·
1 dag gelede
Bavarian Nordic Upgrades Full-Year 2026 Financial Guidance After Strong Travel Health Performance
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S